It mentions that Boston Scientific informed Wall Street that its stent sales for the third quarter of 2006 could drop as much as $50 million from the previous year. Johnson & Johnson's rival Cypher stent also saw a decrease in third quarter sales--down six percent from the same quarter last year, and it's international sales fell three percent.
0 comments
Hide comments
